摘要 : NLRP3 inflammasome plays a pivotal role in the development of acute lung injury (ALI), accelerating IL-1 beta and IL-18 release and inducing lung inflammation. Resveratrol, a natural phytoalexin, has antiinflammatory properties vi... 展开 NLRP3 inflammasome plays a pivotal role in the development of acute lung injury (ALI), accelerating IL-1 beta and IL-18 release and inducing lung inflammation. Resveratrol, a natural phytoalexin, has antiinflammatory properties via inhibition of oxidation, leukocyte priming, and production of inflammatory mediators. In this study, we aimed to investigate the effect of resveratrol on NLRP3 inflammasome in lipopolysaccharide-induced ALI. Mice were intratracheally instilled with 3 mg/kg lipopolysaccharide (LPS) to induce ALI. Resveratrol treatment alleviated the LPS-induced lung pathological damage, lung edema and neutrophil infiltration. In addition, resveratrol reversed the LPS-mediated elevation of IL-1 beta and IL-18 level in the BAL fluids. In lung tissue, resveratrol also inhibited the LPS-induced NLRP3, ASC, caspase-1 mRNA and protein expression, and NLRP3 inflammasome activation. Moreover, resveratrol administration not only suppressed the NF-kappa B p65 nuclear translocation, NF-kappa B activity and ROS production in the LPS-treated mice, but also inhibited the LPS-induced thioredoxin-interacting protein (TXNIP) protein expression and interaction of TXNIP-NLRP3 in lung tissue. Meanwhile, resveratrol obviously induced SIRT1 mRNA and protein expression in the LPS-challenged mice. Taken together, our study suggests that resveratrol protects against LPS-induced lung injury by NLRP3 inflammasome inhibition. These findings further suggest that resveratrol may be of great value in the treatment of ALI and a potential and an effective pharmacological agent for inflammasome-relevant diseases. (C) 2016 Elsevier Masson SAS. All rights reserved. 收起